<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11762">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02126306</url>
  </required_header>
  <id_info>
    <org_study_id>YI1958</org_study_id>
    <nct_id>NCT02126306</nct_id>
  </id_info>
  <brief_title>Beta Glucosylceramide for Treatment of NASH</brief_title>
  <official_title>Beta Glucosylceramide for Treatment of Non Alcoholic Steatohepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oral administration of betaglucosylceramide was shown effective in reducing inflammation in
      animal models and was found safe in humans.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with NASH to receive the treatment versus placebo for 40 weeks followed by  a liver
      biopsy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Liver biopsy score measured by points of the NAS score</measure>
    <time_frame>40 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Decrease of 2 points in the biopsy score</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Compliance Behavior</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Beta Glucosylceramide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Beta Glucosylceramide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beta Glucosylceramide</intervention_name>
    <description>Beta Glucosylceramide</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Beta Glucosylceramide</arm_group_label>
    <other_name>Beta Glucosylceramide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Beta Glucosylceramide</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven NASH

        Exclusion Criteria:

          -  Other therapies
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yaron Ilan, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Hadassah Medical Center</affiliation>
  </overall_official>
  <verification_date>January 2006</verification_date>
  <lastchanged_date>April 28, 2014</lastchanged_date>
  <firstreceived_date>April 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
